ge²p² global
governance, ethics, evidence, policy, practice

Public Consultations Watch :: Global Calls for Input/Public Comment/RFIs

Issue 42 :: 29 July 2026

GE2P2 Global is an integrated non-profit foundation and public benefit corporation formed to advance scientific rigor, ethical resilience, and integrity in research and evidence generation – informing responsible governance, policy, and practice.

In the context of this mission, GE2P2 Global monitors public consultations/calls for input/RFIs and similar opportunities across its focus areas of global health, human rights, humanitarian action, education/literacy, heritage, climate/environment, peace, and sustainable development.

Monitoring this span of sectors yields a broad variety of public comment opportunities, even though this modality is not employed in any uniform way across the UN system, multilateral agencies, INGOs, member states or their ministerial/regulatory bodies. As we are still exploring this monitoring approach and broadening the range of calls included, we stress that this is an indicative and not an exhaustive digest.

In parallel, GE2P2 Global is striving to respond to public consultation opportunities where the experience and expertise of members of our growing community of practice suggest that a meaningful contribution can be developed. The GE2P2 Global Foundation also functions as the secretariat for the Global Forum for Research Ethics and Integrity – a global group of individuals from over 30 countries who collaborate on analysis and action, including response to selected public consultations.

We welcome information about calls for public consultation – at global or country level – to help enrich this digest. Equally, individuals and organizations/institutions interested in collaborating on joint responses to any of the opportunities listed below are welcome to contact us [David R Curry, GE2P2 Global Foundation, david.r.curry@ge2p2global.org].

Acknowledgements: We appreciate the support of Foundation Senior Fellow Gerald Schatz, JD for his continuing support in helping identify calls included in this digest, and Associate Fellow Sedem Adiabu, MPH, for her critical role in the secretariat function which supports development of submissions to selected calls.

Digest content is organized in three sections:

[1] Title and source of all calls organized by due date [p.2 ff]
[2] All calls, listed with more comprehensive information [i.e., objective, scope] organized by due date under thematic areas: Biomedical Research; Environment/Climate; Human Rights+ [p.5 ff]
[3] Selected Supplementary Content including Final, Published Guidances/Regulations/Laws Employing Calls for Public Consultation [p.15 ff]

We expect to add thematic areas as our digest evolves and becomes more comprehensive.

Calls for Public Consultation: Title/Source/Sorted by Due Date

NEW - **Proposed targeted amendments to the Model Reporting Rules for Digital Platforms to support exchange of tax information**
OECD - Public consultation **Submission period 15 June - 14 August 2026**

NEW - **Notice - HHS Request for Comment on the Update to the National Plan To Address Alzheimer's Disease**
Notice by the Health and Human Services Department - 07/24/2026. **Comment period ends 08/15/2026**

Call for Input for OHCHR substantive report on enhancing international cooperation and national efforts to facilitate the repatriation of illicit funds and ensure the effective use of repatriated funds for sustainable development and the realization of economic, social and cultural rights
Office of the High Commissioner for Human Rights **Comments due 17 August 2026**

NIH - Request for Information on Measuring and Rewarding Scientific Impact
NIH Notice Number: NOT-OD-26-087 Release Date: June 18, 2026 **Response Date: August 19, 2026**

Call for Input: Environmental human rights defenders and the human right to a clean, healthy and sustainable environment
Issued by Special Rapporteur on the human right to a healthy environment **Deadline: 21 August 2026**

NEW - **FATF launches public consultation on guidance to increase payment transparency**
Financial Action Task Force (FATF) Please send your **response by Friday 21 August 2026**

NEW - **Call for Inputs for OHCHR Report on the Impact of International Financial Institution Conditionalities on Human Rights (HRC Resolution 59/19)**
Issued by OHCHR **Deadline: 31 August 2026**

Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing
FDA 06/03/2026 FR Document:2026-11054 **Comments on the draft guidance by September 1, 2026**

NEW - **2026 Comprehensive Surveillance Review**
IMF - Public Consultation with Civil Society Organizations (CSOs) from **July 25 – September 15, 2025**

NEW - **Expanded Access to Investigational Drugs for Treatment Use - Agency Information Collection Activities; Proposed Collection; Comment Request**
A Notice by the Food and Drug Administration on 07/28/2026 **Comment period ends on 09/28/2026**

NEW - **Concept paper on the revision of the guideline on data requirements for authorisation of immunological veterinary medicinal products in exceptional circumstances (EMA/CVMP/IWP/251947/2021)**
Draft: consultation open **Consultation dates: 26/06/2026 to 30/09/2026**

FDA Rare Disease Innovation Hub Future Programming; Request for Comments
A Notice by the Food and Drug Administration on 01/30/2026
This document has a **comment period ends 12/31/2026.**

NEW - **Consultation on the digital provision of law: Towards a shared reference framework for law as code**
This OECD consultation seeks input on developing a shared international reference framework for Law as Code—the transformation of enacted laws into machine-executable formats.
Public consultation: 29 Jul 2026 - 1 May 2027

ISO/AWI 14155 - Biological and clinical evaluation of medical devices
ISO/TC 194 Stage 20.00
Due: Ongoing at national standards bodies level

Contribute a tool - Catalogue of Tools & Metrics for Trustworthy AI
OECD-AI Policy Observatory
Contribute your tools and metrics to our catalogue. No deadline date identified.
This catalogue is a platform where AI practitioners from all over the world can share and compare tools and metrics to help make AI trustworthy, build upon each other's efforts to create global good practices, and speed up the process of implementing the OECD AI Principles. This catalogue can only exist with your contributions and those of AI practitioners from all sectors. You can also share your experience using a tool or metric by submitting a use case.
:: Contribute a tool
:: Share your experience using a tool

A framework for evaluating rapidly developing digital and related technologies: AI, large language models and beyond - International Science Council Discussion Paper: Invitation to Comment
International Science Council [ISC]
No submission deadline date identified.

Public Consultation Calls: Purpose/Objective/Scope/Background Information – Sorted by Thematic Area

Biomedical Research/Regulation/Governance

NEW - **Notice - HHS Request for Comment on the Update to the National Plan To Address Alzheimer's Disease**

Notice by the Health and Human Services Department - 07/24/2026. **Comment period ends 08/15/2026**

SUMMARY

HHS released the first National Plan to Address Alzheimer's Disease in 2012, establishing a comprehensive framework to accelerate scientific progress and improve support for individuals living with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) and their families. Since then, the National Plan has been updated annually and has guided federal efforts across research, care delivery, public health, and data infrastructure.

HHS is now updating the overall National Plan to lead federal efforts through 2035. HHS would like input from the public to inform the future direction of federal efforts. Through this RFI, HHS invites public comment on approaches to advancing AD/ADRD research and development of new interventions to prevent and treat dementia, risk reduction strategies, early detection and diagnostic tools, and/or enhanced care, services, and supports for people living with dementia and their families, caregivers, and care partners. The Department also seeks input on gaps, emerging priorities, and opportunities to strengthen coordination across federal, state, Tribal, local, private sector, and community partners.

The purpose of this RFI is to solicit public input to inform the development of a comprehensive update to the National Plan to Address Alzheimer's Disease, including future goals and priorities.

NEW - **Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing**

FDA 06/03/2026 FR Document:2026-11054 **Comments on the draft guidance by September 1, 2026**

Summary

The draft guidance document provides sponsors engaged in the development of human gene therapy (GT) products incorporating ex-vivo and in vivo genome editing (GE) of human somatic cells (GE products) with FDA's recommendations on the type of prior knowledge that may be scientifically appropriate to leverage to advance product development…This draft guidance also provides recommendations on how sponsors may consider leveraging prior knowledge to increase review efficiency and accelerate product development across multiple programs. These recommendations include how to leverage chemistry, manufacturing, and controls; nonclinical; and clinical prior knowledge. The ability to leverage prior knowledge to expedite product development may be particularly helpful in the context of GE products intended to treat rare diseases. While this draft guidance specifically focuses on GE products, some of the recommendations, when finalized, may also be applicable to other cell and GT products, such as adeno-associated viral vectors, nanoparticle-based GT products, and ex vivo-modified cell-based GTs that do not incorporate GE. However, additional considerations may also apply to these related product types, based on the specific product and manufacturing process, that are beyond those recommended in this draft guidance.

NEW - **Expanded Access to Investigational Drugs for Treatment Use - Agency Information Collection Activities; Proposed Collection; Comment Request**

A Notice by the Food and Drug Administration on 07/28/2026 **Comment period ends on 09/28/2026**
OMB Control Number 0910-0814--Revision

This information collection supports Agency regulations in 21 CFR part 312, subpart I, Expanded Access to Investigational Drugs for Treatment Use; associated guidance; and Form FDA 3926, Individual Patient Expanded Access Investigational New Drug Application (IND). The regulations govern the use of investigational new drugs, biologics, and approved drugs, when the primary purpose is to diagnose, monitor, or treat a patient's disease or condition. The goal of the expanded access program is to facilitate the availability of such products to patients with serious diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the patient's disease or condition.

Sometimes called "compassionate use," expanded access (EA) is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. Agency regulations in 21 CFR part 312 provide for individual patient EA and associated procedures for those submitting EA requests to FDA. We provide resource information on our website at https://www.fda.gov/news-events/public-health-focus/expanded-access regarding our EA program, including information for patients, physicians, and industry. We also provide information pertaining to forms and processes for submitting EA requests to FDA.

This information collection accounts for burden associated with the submission of expanded access requests for individual patients and other expanded access submissions, including INDs that involve large groups of patients enrolled for treatment use of the investigational drug (§§ 312.300 through 312.320 (21 CFR 312.300 through 312.320)). We developed electronic Form FDA 3926 to assist respondents with the information collection...

NEW - Concept paper on the revision of the guideline on data requirements for authorisation of immunological veterinary medicinal products in exceptional circumstances (EMA/CVMP/IWP/251947/2021)

Draft: consultation open **Consultation dates: 26/06/2026 to 30/09/2026**
Reference Number: EMA/CVMP/IWP/385629/2025
Summary:
The "Guideline on data requirements for authorisation of immunological veterinary medicinal products in exceptional circumstances" was adopted on 19 January 2022 and came into effect on 28 January 2022. This document was intended to provide advice to manufacturers seeking marketing authorisation in exceptional circumstances related to animal or public health included in Articles 25, 26 and 27 of Regulation (EU) 2019/6, based on a reduced data set regarding quality, safety and efficacy and the benefit of the immediate availability on the market to the animal or public health outweighs the risks arising from the fact that some data are not available. Based on experience with the first marketing authorisation applications submitted under Art. 25, it has become evident that several sections of the guideline require further detail and clarification to ensure consistent interpretation.
Further clarification to ensure consistent understanding and application of the requirements is necessary. Additionally, some relevant references to legal texts and guidance documents should be included. Comments should be provided using the template. The completed comments form should be sent to vet-guidelines@ema.europa.eu

FDA Rare Disease Innovation Hub Future Programming; Request for Comments

A Notice by the Food and Drug Administration on 01/30/2026

This document has a **comment period that ends in 328 days. (12/31/2026)**
SUMMARY:
The Food and Drug Administration (FDA or the Agency) is announcing the following request for comments for a future public workshop series entitled "Rare disease Innovation, Science, and Exploration (RISE) Workshop." The purpose of the public workshops is to focus on challenges that are common to multiple diseases or a class of diseases, and for which evolving science offers innovative solutions. The workshops will primarily focus on cross-cutting or common issues and will not be focused on any specific product under review by the Agency. The Agency further welcomes comments that highlight general rare disease-related issues of potential interest for the FDA Rare Disease Innovation Hub (Hub) to inform its future activities

::::::::::
::::::::::

Human Rights

Call for Input for OHCHR substantive report on enhancing international cooperation and national efforts to facilitate the repatriation of illicit funds and ensure the effective use of repatriated funds for sustainable development and the realization of economic, social and cultural rights

Office of the High Commissioner for Human Rights **Comments due 17 August 2026**
Background
OHCHR has been mandated, pursuant to Human Rights Council Resolution 58/7, to prepare a substantive report on enhancing international cooperation and national efforts to facilitate the repatriation of illicit funds and ensure the effective use of repatriated funds for sustainable development and the realization of economic, social and cultural rights, and to present the report to the Council at its sixty-fourth session.
Objectives
OHCHR invites written contributions, from experts across diverse geographic regions, including from States, relevant intergovernmental organizations, United Nations agencies, funds and programmes, relevant special procedures of the Human Rights Council, the Advisory Committee, treaty bodies, national human rights institutions and civil society representatives, including relevant local government networks and non-governmental organizations.
To facilitate the submission of inputs, OHCHR is circulating a questionnaire on the topic (see below).
Note verbale: English | Français | Español
Questionnaire: English

Call for Input: Environmental human rights defenders and the human right to a clean, healthy and sustainable environment

Issued by Special Rapporteur on the human right to a healthy environment **Deadline: 21 August 2026**
…Objectives
In this report, the Special Rapporteur examines the situation of environmental human rights defenders, working in the context of the triple planetary crises, focusing on how violations against them also affect the realization of the human right to a clean, healthy and sustainable environment. The report will outline the obligations of States and non-State actors, under international law and human rights law, to protect EHRDs, as well as States' duty to protect the environment and the climate system, preventing further harms. In doing so, the Special Rapporteur aims to contribute to the understanding of the situation of EHRDs from an individual and a collective perspective, acknowledging that while many of

EHRDs are leading and implementing individual actions, these are commonly part of broader community or collective efforts.
The Special Rapporteur will provide concrete recommendations to States and other stakeholders to ensure the protection of environmental human rights defenders and the effective implementation of the right to a healthy environment, including in relation to collective measures from an intersectional approach.

NEW - Call for Inputs for OHCHR Report on the Impact of International Financial Institution Conditionalities on Human Rights (HRC Resolution 59/19)

Issued by OHCHR **Deadline: 31 August 2026**
Objectives
Through this consultation process, OHCHR seeks to:

- Gather evidence on how IFI conditionalities have been designed, negotiated, implemented and contested since 2020, and their effects on the enjoyment of human rights, including economic, social and cultural rights;
- Identify challenges encountered and good practices developed by different stakeholders in engaging with conditionality processes;
- Solicit views on the adequacy of existing accountability and redress mechanisms;
- Inform actionable recommendations for IFIs, States and the United Nations system.

"IFI conditionalities" refers to policy changes that governments are required to implement as a condition for receiving financial support from IFIs, rather than measures chosen freely by governments in the normal course of economic policy-making. The scope of the report covers conditionality programmes from 2020 onwards.

NEW - Call for Inputs: Child Rights and Safety in the Digital Environment

Issued by OHCHR **Deadline: 30 October 2026**
Purpose:
OHCHR seeks inputs from stakeholders to inform its substantive report on Children's Rights and Safety in the Digital Environment, to be presented to the Human Rights Council at its 64th session (February to March 2027).
Background
In its Resolution 56/6, the Human Rights Council requested the Office of the United Nations High Commissioner for Human Rights to convene five regional consultations to assess the risks to the safety of the child in the digital environment and best practices to address these risks in different geographical areas, bearing in mind current and emerging business models. The resolution also requests OHCHR to prepare a report containing a summary of those consultations, in an accessible and child-friendly format, which includes recommendations from the different stakeholders. The report will be presented to the Human Rights Council at its 64th session (February – March 2027), and will inform an interactive dialogue among States, which may lead to HRC-mandated follow-up.
Documents: Concept Note (English | Français | Español)

::::::::::
::::::::::

Emerging/Disruptive Technologies

:: Call for Public Consultation

No new calls identified.

:: Resources, Events

No new resources, events identified.

::::::::::
::::::::::

Biodiversity/Environment/Climate/Disaster Mitigation

:: Call for Public Consultation

:: Resources, Events

No new resources, events identified.

::::::::::
::::::::::

Science Integrity/Evidence to Policy/ Open Science

:: Calls for Public Consultation

NIH - Request for Information on Measuring and Rewarding Scientific Impact

NIH Notice Number: NOT-OD-26-087 Release Date: June 18, 2026 **Response Date: August 19, 2026**

Purpose

Biomedical research has increasingly become a collaborative and interdisciplinary enterprise that relies on transparent reporting, rigorous replication, careful interpretation of methods and analyses, and the iterative refinement of scientific knowledge. In recognition of this evolution, NIH seeks public input on the defining features of modern 21st-century science that should be measured, recognized, and incentivized…

Information Requested

To support efforts, NIH is engaging stakeholders in defining specific, measurable indicators and incentives that reflect the collaborative, rigorous, and mission-driven nature of modern biomedical science. Comments are welcome on all potential possible indicators and incentives, but are specifically encouraged on the following:

- *Rigor and Reproducibility.* Reproducible and replicable biomedical approaches are foundational to rigorous research. New strategies are needed to identify areas ripe for replication and reproducibility efforts, as well as incentives and infrastructure to support the reproduction and replication of existing findings. NIH also seeks comment on rigor, including with regard to defining causal research.
- *Data, Software, and Model Sharing.* Sharing scientific data and tools accelerates biomedical research discovery, in part, by enabling validation of research results, providing accessibility to high-value datasets, and promoting data reuse for future research studies. NIH seeks to incentivize and reward these activities to maximize the value of research investments, catalyze collaborations, and accelerate scientific impact.
- *Training and Mentorship.* NIH recognizes that advancing its mission requires promoting the growth and stability of the biomedical research workforce. While NIH supports training and protects time through existing policies and programs, additional indicators are needed to assess and quantify the impact of these efforts.

- *Collaboration.* As biomedical research becomes increasingly interdisciplinary and convergent, collaboration is growing in both scale and complexity. NIH seeks new approaches for assessing and recognizing contributions to team-based science.
- *Entrepreneurship and Translation*. To advance the translation of discoveries into products for people, NIH fosters the maturation of discoveries from bench to bedside and promotes innovation across sectors. More can be done to incentivize, assess, and integrate the impact of innovation and entrepreneurial efforts as critical to the NIH mission.
- *Foundational Scientific Exploration.* Basic research and high-risk, high-reward initiatives represent foundational scientific exploration with an inherent risk of failure but the potential for paradigm-shifting breakthroughs. Further embedding these approaches within the academic enterprise is essential to ensuring continued support for bold and innovative research directions.
- *Public Impact.* NIH seeks approaches for assessing and recognizing the broader public impact of biomedical research, including contributions to health outcomes, economic growth, clinical practice, public trust, accessibility, and societal benefit.

The NIH is particularly interested in comments that include specific examples of measurable indicators, implementation approaches, potential benefits or unintended consequences, and considerations for feasibility across career stages, disciplines, and institution types.

:: Resources, Events

No new resources, events identified.

::::::::::

Heritage/Cultural Assets

:: Call for Public Consultation

No new calls identified.

:: Resources, Events

No new resources, events identified.

::::::::::
::::::::::

Governance, Peace, Trade, Global Finance

:: Call for Public Consultation

NEW - **Proposed targeted amendments to the Model Reporting Rules for Digital Platforms to support exchange of tax information**

OECD - Public consultation **Submission period 15 June - 14 August 2026**

About

The Model Rules for Reporting by Platform Operators with respect to Sellers in the Sharing and Gig Economy (MRDP) were approved by the OECD in 2020 and complemented in 2021 by an Optional Module extending their scope to the sale of goods and the rental of means of transportation. The implementation of the Model Rules across more than 30 jurisdictions and initial practical experience has resulted in the identification of a set of issues with the operation of the Model Rules by implementing jurisdictions, representatives of the platform industry, and academia. While some have been addressed through interpretative guidance, including FAQs, other issues may be more effectively addressed

through targeted amendments to the Model Rules, the Optional Module and/or the related Commentaries.

Background

To this end, a consultation document is released for public input:

Proposed Targeted Amendments to the Model Reporting Rules for Digital Platforms

The consultation document presents a set of proposed revisions, including:

- proposed amendments to the thresholds for excluding sellers engaged in low-value goods transactions;
- proposals to clarify the definitions of "Platform" and "Platform Operator", as well as the related Commentary, with a view to addressing divergent interpretations;
- a proposed limitation of transactional reporting where a seller is itself a Reporting Platform Operator; and the introduction of a "Related Entity" concept to exclude certain intra-group platform arrangements from the scope of reporting. Separately delegates are still considering possible approaches to improve reporting outcomes in relation to intermediary sellers.

NEW - FATF launches public consultation on guidance to increase payment transparency

Financial Action Task Force (FATF) Please send your **response by Friday 21 August 2026**

Draft R16. Guidance for consultation

Paris, 24 June 2026 - The Financial Action Task Force (FATF) is inviting views of stakeholders from across industry and civil society on new guidance to support the implementation of strengthened FATF Standards on payment transparency when they come into effect.

The revisions to FATF's Recommendation16, agreed in June 2025, will keep pace with changes in the payment landscape, and strengthen the safety and security of the international payment system by increasing transparency of information that accompanies cross-border payments and requiring the introduction of tools to protect against fraud and error. All countries around the world are expected to be ready to implement the changes by the end of 2030.

The FATF wants to hear from as many stakeholders as possible, including financial institutions worldwide with different business models and capacity, payment system operators, civil society and the research community. Input from emerging economies and lower-capacity jurisdictions is particularly welcome. Feedback is invited on a range of issues including whether the guidance provides sufficient clarity and support on:

- Detecting and preventing misdirected payments, including by leveraging the three options for alignment checks foreseen in the revised Standard;
- Implementation that supports financial inclusion, including in lower-capacity jurisdictions;
- How Recommendation16 applies to newer payment methods, such as digital wallets and mobile money; and
- Implementing Recommendation16 and meeting data protection and privacy requirements together.
- The full list of consultation questions is set out in the explanatory memorandum to the draft Guidance

The Financial Action Task Force (FATF) leads global action to tackle money laundering, terrorist and proliferation financing. The 40-member body sets international standards to ensure national authorities can effectively go after illicit funds linked to drugs trafficking, the illicit arms trade, cyber fraud and other serious crimes.

NEW - 2026 Comprehensive Surveillance Review

IMF - Public Consultation with Civil Society Organizations (CSOs) from **July 25 – September 15, 2025**

Take the Survey: English | Español | Français | Русский

The IMF is currently conducting a periodic review of its surveillance – the 2026 Comprehensive Surveillance Review (CSR) – to strengthen the IMF's ability to support member countries and global economic stability. As part of this review, the IMF is consulting with its members and other stakeholders, including non-media and non-governmental organizations, such as Civil Society Organizations (CSOs), to canvas their views on the direction of IMF surveillance over the next 5-10 years.

The 2026 CSR report presenting staff's findings and recommendations will be submitted to the IMF's Executive Board for consideration and approval next year. The views of all stakeholders, including CSOs who participate in this consultation process, will help inform the report.

About the 2026 CSR: Objectives and scope

IMF surveillance refers to the monitoring of and provision of advice on the economic and financial policies of member countries, alongside the oversight of the International Monetary System (IMS) to ensure its effective operation.[1] Surveillance is an essential and integral part of the IMF's mandate and is established in the IMF's articles of agreement and modernized in the 2012 Integrated Surveillance Decision (2012 ISD). You can find more information on the IMF surveillance here.

NEW - Consultation on the digital provision of law: Towards a shared reference framework for law as code

This OECD consultation seeks input on developing a shared international reference framework for Law as Code—the transformation of enacted laws into machine-executable formats.

Public consultation: 29 Jul 2026 - 1 May 2027

Law as Code raises legal, institutional, organisational, and technical questions that cannot be resolved through isolated projects alone. These include how machine-executable legal logic should be modelled, legally reviewed, authorised, versioned, maintained, provided, and governed, and which institutions should be responsible for each of these functions.

The OECD consultation therefore seeks to establish a shared understanding of Law as Code and to develop an international reference framework, defining common principles, structures, and requirements for its implementation as public digital infrastructure. The objective is not to prescribe a single technical system or institutional model, but to provide a common foundation for trustworthy and interoperable approaches, consistent with each jurisdiction's constitutional and legal framework.

The consultation is structured in three phases:

Phase 1: Mapping the current landscape — July to mid-October 2026:

A survey will map existing Law as Code initiatives. It includes a general section, "Digital law in your context", requiring only a high-level understanding of how law is provided digitally in the relevant jurisdiction, and a specialist section, "Existing Law as Code initiatives", requesting technical details about existing initiatives. Respondents may complete only the sections relevant to their knowledge.

Phase 2: Developing principles and requirements — mid-September to mid-November 2026:

A second survey will gather perspectives on the principles, requirements and technical architecture that should inform the reference framework. Contributions are invited from participants with policy, legal, technical and other relevant expertise.

Phase 3: Developing the reference framework — November 2026 to the end of April 2027:

This phase will bring together experts from across the international Law as Code community in a collaborative online process to exchange perspectives and jointly work on the development of a shared reference framework.

A final publication, bringing together the results of all three phases together with the draft reference framework, is expected in late 2027 or early 2028. The project is funded by SPRIND, the German Federal Agency for Breakthrough Innovation.

:: Resources, Events

No new resources, events identified.

::::::::::
::::::::::

Selected Final, Published Guidances, Frameworks, Regulations, Meetings Employing Calls for Public Consultation

M15 General Principles for Model-Informed Drug Development; International Council for Harmonisation; Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 06/03/2026 **Final Guidance**

SUMMARY:

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "M15 General Principles for Model-Informed Drug Development." The guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guidance provides general recommendations for the planning, model evaluation, and documentation of evidence derived from model-informed drug development (MIDD). It establishes a harmonized assessment framework (including the associated terminology) for the MIDD evidence. It also provides recommendations for related regulatory interactions, reporting, and submission. This guideline is intended to facilitate a multidisciplinary understanding of MIDD and associated evidence generation. The guidance finalizes the draft guidance of the same title issued on December 30, 2024.

::::::::::
::::::::::

Selected Peer-reviewed Journal Literature/Gray Lit Integrating Public Consultation

OECD Guidelines for Citizen Participation Processes

Paris: OECD Publishing. 2022
https://www.oecd-ilibrary.org/governance/oecd-guidelines-for-citizen-participation-processes_f765caf6-en [Accessed 10 Nov 2023]

The *OECD Guidelines for Citizen Participation Processes* are intended for any public official or public institution interested in carrying out a citizen participation process. The guidelines describe ten steps for designing, planning, implementing and evaluating a citizen participation process, and discuss eight different methods for involving citizens: information and data, open meetings, public consultations, open innovation, citizen science, civic monitoring, participatory budgeting and representative deliberative processes. The guidelines are illustrated with examples as well as practical guidance built on evidence gathered by the OECD. Finally, nine guiding principles are presented to help ensure the quality of these processes.

::::::::::
::::::::::

Selected Resources for Public Consultation Notices, Calls, Processes

UNHCHR UN High Commissioner for Human Rights – Calls for Input

https://www.ohchr.org/en/calls-for-input-listing

UNESCO - Consultations
https://www.unesco.org/en/search?category=UNESCO&text=consultation&category=UNESCO&sort_by=unesco_date#toggle-facets

WHO – Public Consultations
https://www.who.int/home/search?indexCatalogue=genericsearchindex1&searchQuery=public%20consultation&wordsMode=AnyWord

OECD - Consultations and calls for contributions
https://www.oecd.org/about/civil-society/consultations-and-calls-for-contributions.htm

IFAD Public Consultations
https://webapps.ifad.org/members/executive-board-public-consultation

European Medicines Agency's (EMA) open public consultations
https://www.ema.europa.eu/en/news-events/open-consultations

U.S. Federal Register – "Public Comment" or RFI
https://www.federalregister.gov/documents/search?conditions%5Bpublication_date%5D%5Bgte%5D=09%2F13%2F2023&conditions%5Bterm%5D=%22public+comment%22+or+RFI#

U.S. HHS – Open Requests for Comments
https://www.hhs.gov/ohrp/regulations-and-policy/requests-for-comments/index.html

* * * *